- Home
- FBRT vs GERN Comparison
FBRT vs GERN Comparison
Compare FBRT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | GERN |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 900.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FBRT | GERN |
|---|---|---|
| Price | $9.28 | $1.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.00 | $2.90 |
| AVG Volume (30 Days) | 1.2M | ★ 16.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.99 | $32.27 |
| Revenue Next Year | N/A | $60.16 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.42 | $1.04 |
| 52 Week High | $13.58 | $2.01 |
Technical Indicators
Market Signals| Indicator | FBRT | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 51.38 |
| Support Level | $8.42 | $1.20 |
| Resistance Level | $10.98 | $1.68 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 44.96 | 33.35 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.